LGE-899 | CAS#1221722-10-6 | bioactive chemical

MedKoo Cat#: 598785 | Name: LGE-899

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LGE-899 is a bioactive chemical.

Chemical Structure

LGE-899

CAS#1221722-10-6

Theoretical Analysis

MedKoo Cat#: 598785

Name: LGE-899

CAS#: 1221722-10-6

Chemical Formula: C15H11F3O3

Exact Mass: 296.0660

Molecular Weight: 296.25

Elemental Analysis: C, 60.82; H, 3.74; F, 19.24; O, 16.20

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

LGE-899; LGE 899; LGE899; Sonidegib metabolite M48;

IUPAC/Chemical Name

2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxylic acid

InChi Key

LNRROOUNLXDADK-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H11F3O3/c1-9-12(3-2-4-13(9)14(19)20)10-5-7-11(8-6-10)21-15(16,17)18/h2-8H,1H3,(H,19,20)

SMILES Code

O=C(C1=C(C)C(C2=CC=C(OC(F)(F)F)C=C2)=CC=C1)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Sonidegib metabolite M48 is the main circulating metabolite of Sonidegib. Sonidegib is a hedgehog pathway inhibitor. M48 showed a much longer Tmax (60 h) than Sonidegib.

In vitro activity:

Sonidegib significantly suppressed proliferation in NKTCL cells and the effect was dose-dependent. Further analysis revealed that sonidegib treatment elevated the number of apoptotic cells in a dose- and time-dependent manner. Reference: Med Sci Monit. 2019 Nov 14;25:8579-8586. https://pubmed.ncbi.nlm.nih.gov/31724562/

In vivo activity:

Consistent with these findings, orally administered sonidegib attenuated IL-6 and TNF-α levels in the brains of LPS-treated mice. Collectively, these results indicate that sonidegib suppresses inflammation and cell migration in LPS-treated BV2 cells and mice by inhibiting JNK and NF-κB signaling. Reference: Int J Mol Sci. 2022 Sep 13;23(18):10590. https://pubmed.ncbi.nlm.nih.gov/36142500/

Preparing Stock Solutions

The following data is based on the product molecular weight 296.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Liu S, Li C, Xin P, Zheng Y, Peng Q, Xu Y, Luo Y, Wu Y, Zhu X. Sonidegib, a Smoothened Inhibitor, Promotes Apoptosis and Suppresses Proliferation of Natural Killer/T-Cell Lymphoma. Med Sci Monit. 2019 Nov 14;25:8579-8586. doi: 10.12659/MSM.918812. PMID: 31724562; PMCID: PMC6873646. 2. Al Mamun Bhuyan A, Sahu I, Cao H, Lang F. Sonidegib, a Novel Inhibitor of Suicidal Erythrocyte Death. Cell Physiol Biochem. 2018;47(4):1352-1364. doi: 10.1159/000490820. Epub 2018 Jun 19. PMID: 29929201. 3. Nguyen NM, Duong MTH, Bui BP, Nguyen PL, Chen X, Cho J, Ahn HC. Sonidegib Suppresses Production of Inflammatory Mediators and Cell Migration in BV2 Microglial Cells and Mice Treated with Lipopolysaccharide via JNK and NF-κB Inhibition. Int J Mol Sci. 2022 Sep 13;23(18):10590. doi: 10.3390/ijms231810590. PMID: 36142500; PMCID: PMC9503982. 4. Spetz J, Langen B, Rudqvist N, Parris TZ, Helou K, Nilsson O, Forssell-Aronsson E. Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice. BMC Cancer. 2017 Aug 8;17(1):528. doi: 10.1186/s12885-017-3524-x. PMID: 28789624; PMCID: PMC5549301.

In vitro protocol:

In vivo protocol:

1. Nguyen NM, Duong MTH, Bui BP, Nguyen PL, Chen X, Cho J, Ahn HC. Sonidegib Suppresses Production of Inflammatory Mediators and Cell Migration in BV2 Microglial Cells and Mice Treated with Lipopolysaccharide via JNK and NF-κB Inhibition. Int J Mol Sci. 2022 Sep 13;23(18):10590. doi: 10.3390/ijms231810590. PMID: 36142500; PMCID: PMC9503982. 2. Spetz J, Langen B, Rudqvist N, Parris TZ, Helou K, Nilsson O, Forssell-Aronsson E. Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice. BMC Cancer. 2017 Aug 8;17(1):528. doi: 10.1186/s12885-017-3524-x. PMID: 28789624; PMCID: PMC5549301.